Last Updated:
10 Mar 2026, 03:30:01 PM (IST)
Zydus Lifesciences Limited
NSE: ZYDUSLIFE BSE: ZYDUSLIFE
NSE
923.10
14.25 (1.57%)
Prev Close
908.85
Open Price
915
Volume
548,985
Today Low / High
909 / 927
52 WK Low / High
795 / 1059.05
Range
877 - 969
BSE
922.90
14.25 (1.57%)
Prev Close
908.65
Open Price
908.75
Volume
10,700
Today Low / High
908.75 / 927.6
52 WK Low / High
797.05 / 1059
Range
877 - 969
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 923.1 (target range: 877 - 969), reflecting a change of 14.25 (1.56792%). On the BSE, it is listed at 922.9 (target range: 877 - 969), showing a change of 14.25 (1.56826%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
02 Mar
893.65
1.48%
27 Feb
939.90
-1.94%
26 Feb
928.00
1.13%
25 Feb
903.50
1.79%
24 Feb
902.05
0.20%
23 Feb
906.95
0.11%
20 Feb
905.80
-0.56%
19 Feb
919.75
-1.89%
18 Feb
910.00
0.01%
Zydus Lifesciences Limited Graph
Zydus Lifesciences Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Zydus Lifesciences Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 923.10, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 922.90 | 932.13 | 838.92 - 1,025.34 |
| 941.36 | 753.09 - 1,129.63 | ||
| 950.59 | 665.41 - 1,235.76 | ||
| Bearish Scenario | 922.90 | 913.67 | 822.30 - 1,005.04 |
| 904.44 | 723.55 - 1,085.33 | ||
| 895.21 | 626.65 - 1,163.78 |
Overview of Zydus Lifesciences Limited
ISIN
INE010B01027
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
664,158
Market Cap
912,553,605,531
Last Dividend
11
Official Website
IPO Date
2002-07-01
DCF Diff
-1,826.47
DCF
2,750
Financial Ratios Every Investor Needs
Stock Dividend of ZYDUSLIFE
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-07-25 | July 25, 25 | 11 | 11 | 2025-07-25 | 2025-08-14 | |
| 2024-07-26 | July 26, 24 | 3 | 3 | 2024-07-26 | 2024-09-08 | |
| 2023-07-27 | July 27, 23 | 6 | 6 | 2023-07-28 | 2023-09-10 | |
| 2022-07-28 | July 28, 22 | 2.5 | 2.5 | 2022-07-29 | 2022-08-16 | |
| 2021-07-28 | July 28, 21 | 3.5 | 3.5 | 2021-07-29 | 2021-09-10 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 23,241.50 Cr | 6,538.40 Cr | 16,703.10 Cr | 0.7187 | 1,944.90 Cr | 3,711.80 Cr | 9,603.70 Cr | 4,525.50 Cr | 44.97 | 6,830.30 Cr | 0.1947 |
| 2024-03-31 | 19,547.40 Cr | 6,393.70 Cr | 13,153.70 Cr | 0.6729 | 1,312.50 Cr | 3,164.00 Cr | 7,595.50 Cr | 3,859.50 Cr | 37.91 | 5,257.20 Cr | 0.1974 |
| 2023-03-31 | 17,237.40 Cr | 6,470.70 Cr | 10,766.70 Cr | 0.6246 | 1,240.80 Cr | 2,788.60 Cr | 5,761.00 Cr | 1,960.30 Cr | 19.35 | 3,534.40 Cr | 0.1137 |
| 2022-03-31 | 15,109.90 Cr | 5,685.70 Cr | 9,424.20 Cr | 0.6237 | 1,045.50 Cr | 2,457.30 Cr | 5,128.90 Cr | 4,487.30 Cr | 21.90 | 3,169.50 Cr | 0.2970 |
| 2021-03-31 | 14,403.50 Cr | 4,943.40 Cr | 9,460.10 Cr | 0.6568 | 1,124.80 Cr | 2,317.90 Cr | 5,210.30 Cr | 2,133.60 Cr | 21.51 | 3,415.20 Cr | 0.1481 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 826.80 Cr | 37,201.70 Cr | 10,843.30 Cr | 23,953.1000 Cr | 3,213.20 Cr | 256.40 Cr | 3,944.00 Cr | 7,359.90 Cr | 72.90 Cr | 0.90 Cr | 1,556.70 Cr | 9,041.6000 Cr |
| 2024-03-31 | 413.00 Cr | 29,280.80 Cr | 7,179.20 Cr | 19,829.5000 Cr | 804.20 Cr | 391.20 Cr | 3,441.90 Cr | 6,914.80 Cr | 0.00 Cr | 1.80 Cr | 11.20 Cr | 5,341.9000 Cr |
| 2023-03-31 | 487.80 Cr | 25,756.40 Cr | 6,068.10 Cr | 17,515.8000 Cr | 1,194.90 Cr | 707.10 Cr | 3,413.30 Cr | 6,826.70 Cr | 1,960.10 Cr | 29.50 Cr | 1,362.60 Cr | 5,530.7000 Cr |
| 2022-03-31 | 657.80 Cr | 27,795.40 Cr | 8,741.60 Cr | 16,999.6000 Cr | 4,220.90 Cr | 3,563.10 Cr | 3,719.40 Cr | 6,422.60 Cr | 1,824.40 Cr | 28.70 Cr | 1,140.10 Cr | 7,839.4000 Cr |
| 2021-03-31 | 665.20 Cr | 23,884.70 Cr | 8,955.10 Cr | 12,992.3000 Cr | 4,607.60 Cr | 3,942.40 Cr | 3,236.20 Cr | 6,333.20 Cr | 1,648.30 Cr | 22.70 Cr | 224.70 Cr | 7,861.3000 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 6,776.7000 Cr | -8,372.3000 Cr | 2,014.2000 Cr | 5,064.1000 Cr | 413.8000 Cr | 826.8000 Cr | -1,712.6000 Cr | 4,525.5000 Cr | 2,402.0000 Cr | -302.5000 Cr | -444.9000 Cr |
| 2024-03-31 | 3,196.3000 Cr | -1,475.2000 Cr | -1,778.8000 Cr | 2,321.3000 Cr | -74.8000 Cr | 413.0000 Cr | -906.6000 Cr | 3,859.5000 Cr | -392.9000 Cr | -621.0000 Cr | -2.0000 Cr |
| 2023-03-31 | 2,688.8000 Cr | 1,171.2000 Cr | -4,400.4000 Cr | 1,657.9000 Cr | -533.8000 Cr | 573.1000 Cr | -1,030.9000 Cr | 2,582.7000 Cr | -3,147.2000 Cr | -267.1000 Cr | 440.7000 Cr |
| 2022-03-31 | 2,104.1000 Cr | -1,000.3000 Cr | -868.3000 Cr | 901.5000 Cr | 218.6000 Cr | 3,460.1000 Cr | -1,202.6000 Cr | 5,232.3000 Cr | -383.7000 Cr | -372.2000 Cr | -525.5000 Cr |
| 2021-03-31 | 3,293.0000 Cr | -722.5000 Cr | -2,548.9000 Cr | 2,439.0000 Cr | -90.5000 Cr | 1,087.2000 Cr | -854.0000 Cr | 2,284.8000 Cr | -3,342.7000 Cr | -1.5000 Cr | -479.7000 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 6,864.50 Cr | 3,335.60 Cr | 3,528.90 Cr | 0.5141 | 1,292.40 Cr | 1,042.10 Cr | 10.36 | 1,842.90 Cr | 0.1518 |
| 2025-09-30 | 6,123.20 Cr | 3,026.60 Cr | 3,096.60 Cr | 0.5057 | 1,299.80 Cr | 1,258.60 Cr | 12.51 | 2,090.60 Cr | 0.2055 |
| 2025-06-30 | 6,573.70 Cr | 1,789.50 Cr | 4,784.20 Cr | 0.7278 | 3,779.00 Cr | 1,466.80 Cr | 14.58 | 2,010.83 Cr | 0.2231 |
| 2025-03-31 | 6,527.90 Cr | 1,897.50 Cr | 4,630.40 Cr | 0.7093 | 240.20 Cr | 1,170.90 Cr | 11.64 | 2,125.43 Cr | 0.1794 |
| 2024-12-31 | 5,269.10 Cr | 1,583.40 Cr | 3,685.70 Cr | 0.6995 | 2,739.20 Cr | 1,023.50 Cr | 10.17 | 1,155.50 Cr | 0.1942 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 2,782.50 Cr | 4,286.00 Cr | 7,068.50 Cr | 4,975.70 Cr | 4,750.10 Cr | 18,312.90 Cr | 8,289.10 Cr | 46,897.30 Cr | 18,807.40 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 5,637.20 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -26,358.40 Cr |
| 2025-03-31 | 826.80 Cr | 7,001.40 Cr | 7,807.90 Cr | 4,024.70 Cr | 3,944.00 Cr | 17,046.10 Cr | 7,359.90 Cr | 37,201.70 Cr | 10,843.30 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 2,495.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -24,154.60 Cr |
| 2024-09-30 | 1,593.60 Cr | 901.40 Cr | 2,495.00 Cr | 4,671.00 Cr | 3,716.90 Cr | 12,156.90 Cr | 7,153.10 Cr | 31,445.90 Cr | 7,291.30 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 1,466.80 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 1,170.90 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 1,023.50 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 911.20 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 1,419.90 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2015-10-06 | October 06, 15 | 5:1 |
| 2010-04-05 | April 05, 10 | 3:2 |
| 2006-08-30 | August 30, 06 | 2:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,812.80 | ₹4,349,514,433,616.00 | ₹3,298,187.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,372.00 | ₹1,691,565,791,760.00 | ₹298,134.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹4,427.80 | ₹1,498,568,719,232.00 | ₹373,853.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,314.60 | ₹1,094,510,791,983.00 | ₹2,328,593.00 |
| Lupin Limited | LUPIN | ₹2,337.40 | ₹1,068,292,308,200.00 | ₹1,118,737.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹923.10 | ₹928,854,596,169.00 | ₹548,985.00 |
| Mankind Pharma Limited | MANKIND | ₹2,237.70 | ₹923,733,909,614.00 | ₹1,043,890.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,285.90 | ₹746,852,807,016.00 | ₹2,197,557.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,616.50 | ₹671,536,822,500.00 | ₹127,559.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,225.80 | ₹628,122,560,672.00 | ₹1,554,299.00 |
| Laurus Labs Limited | LAURUSLABS | ₹1,038.00 | ₹560,371,132,116.00 | ₹1,367,251.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,491.20 | ₹378,323,729,882.00 | ₹56,999.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,999.90 | ₹374,794,378,438.00 | ₹123,025.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹2,117.40 | ₹339,967,004,084.00 | ₹706,890.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,567.80 | ₹297,211,828,212.00 | ₹871,597.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,815.50 | ₹220,387,500,000.00 | ₹3,477.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,327.40 | ₹215,692,105,131.00 | ₹576,727.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹1,039.20 | ₹186,130,976,904.00 | ₹2,029,982.00 |
| Eris Lifesciences Limited | ERIS | ₹1,351.10 | ₹184,042,641,430.00 | ₹100,690.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹12,597.00 | ₹161,618,111,733.00 | ₹24,766.00 |
| Granules India Limited | GRANULES | ₹581.30 | ₹141,063,489,700.00 | ₹712,670.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹712.35 | ₹140,021,741,381.00 | ₹50,451.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹812.35 | ₹128,651,664,788.00 | ₹293,109.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,684.10 | ₹128,011,297,234.00 | ₹43,345.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹940.65 | ₹115,451,618,400.00 | ₹42,515.00 |
| Cohance Lifesciences Limited | COHANCE | ₹295.60 | ₹113,086,846,584.00 | ₹907,550.00 |
| Viyash Scientific Limited | VIYASH | ₹197.45 | ₹86,151,137,188.00 | ₹1,162,070.00 |
| Procter & Gamble Health Limited | PGHL | ₹4,892.10 | ₹81,205,836,682.00 | ₹11,986.00 |
| Strides Pharma Science Limited | STAR | ₹872.90 | ₹80,457,562,051.00 | ₹160,822.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹500.60 | ₹76,642,890,235.00 | ₹265,090.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹338.65 | ₹66,233,781,988.00 | ₹758,443.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹686.70 | ₹62,254,676,925.00 | ₹118,363.00 |
| FDC Limited | FDC | ₹378.05 | ₹61,550,352,256.00 | ₹52,686.00 |
| Sequent Scientific Limited | SEQUENT | ₹202.40 | ₹50,564,340,966.00 | ₹13,647.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹124.37 | ₹40,360,749,900.00 | ₹1,617,219.00 |
| Innova Captab Limited | INNOVACAP | ₹703.35 | ₹40,249,153,812.00 | ₹21,279.00 |
| Suven Life Sciences Limited | SUVEN | ₹144.43 | ₹33,500,801,218.00 | ₹421,279.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹301.45 | ₹32,847,579,134.00 | ₹64,137.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹353.45 | ₹32,259,381,500.00 | ₹243,536.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹1,908.60 | ₹31,566,364,029.00 | ₹7,443.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹289.65 | ₹29,046,827,863.00 | ₹71,884.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹509.55 | ₹25,843,919,953.00 | ₹191,509.00 |
Key Executives
MD & Executive Director
Sharvil Pankajbhai Patel
Gender: Not Specified
Year Born: 1979
Head of Investor Relations
Arvind Bothra
Gender: male
Year Born:
Company Secretary & Compliance Officer
Dhaval Narendra Soni
Gender: male
Year Born:
President of Special Projects
Nitinkumar Dalsukhray Parekh
Gender: male
Year Born: 1961
President & CEO of America
Punit Patel
Gender: male
Year Born:
President of Finance & Chief Financial Officer
Tushar Dhansukh Shroff
Gender: male
Year Born: 1970
President of Parenteral Operations
Vikram Shukla
Gender: male
Year Born: 1974
FAQs about Zydus Lifesciences Limited
Who is the CEO of the company?
The CEO is Punit Patel.
What is the current market price of the stock?
The current price is ₹906.90.
What is the 52-week price range?
The range is ₹795-1059.05.
What is the market capitalization of the company?
The market capitalization is ₹91,255.36 crores.
What is the dividend yield?
The dividend yield is 1.21%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 18.48.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Zydus Lifesciences Limited (ISIN: INE010B01027) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹91,255.36 crores and an average daily volume of 664,158 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹11.